POST-MARKETING DRUGS STUDIES REGULATION

That this House is deeply concerned that post-marketing drugs studies are being used for commercial and not scientific reasons by some drugs companies; notes that recent research has shown that tens of thousands of diabetics in less developed countries have been put on expensive new medication which does not have additional clinical benefits due to lax international regulations; further notes that some patients are spending a third of their household incomes on the new medication; and calls for the Government to hold discussions on tightening international regulations on post-marketing studies by drugs companies.